nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—bronchus—esophageal cancer	0.018	0.0864	CbGeAlD
Lithium—GSK3B—epithelium—esophageal cancer	0.0179	0.0861	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—esophageal cancer	0.0173	0.0829	CbGeAlD
Lithium—Clonus—Cisplatin—esophageal cancer	0.0169	0.125	CcSEcCtD
Lithium—IMPA2—trachea—esophageal cancer	0.0162	0.0776	CbGeAlD
Lithium—GSK3A—bronchus—esophageal cancer	0.0153	0.0737	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—esophageal cancer	0.015	0.0721	CbGeAlD
Lithium—IMPA2—digestive system—esophageal cancer	0.0139	0.0667	CbGeAlD
Lithium—GSK3A—trachea—esophageal cancer	0.0138	0.0662	CbGeAlD
Lithium—GSK3B—digestive system—esophageal cancer	0.0136	0.0655	CbGeAlD
Lithium—GSK3A—digestive system—esophageal cancer	0.0119	0.0569	CbGeAlD
Lithium—IMPA2—lung—esophageal cancer	0.0116	0.0557	CbGeAlD
Lithium—GSK3B—lung—esophageal cancer	0.0114	0.0547	CbGeAlD
Lithium—GSK3A—lung—esophageal cancer	0.0099	0.0475	CbGeAlD
Lithium—IMPA2—lymph node—esophageal cancer	0.00794	0.0381	CbGeAlD
Lithium—GSK3B—lymph node—esophageal cancer	0.00779	0.0374	CbGeAlD
Lithium—GSK3A—lymph node—esophageal cancer	0.00677	0.0325	CbGeAlD
Lithium—Papilloedema—Cisplatin—esophageal cancer	0.00611	0.0454	CcSEcCtD
Lithium—Slurred speech—Cisplatin—esophageal cancer	0.00434	0.0323	CcSEcCtD
Lithium—Blindness—Cisplatin—esophageal cancer	0.00351	0.0261	CcSEcCtD
Lithium—Taste metallic—Methotrexate—esophageal cancer	0.00335	0.0249	CcSEcCtD
Lithium—Optic neuritis—Cisplatin—esophageal cancer	0.00316	0.0235	CcSEcCtD
Lithium—Chest tightness—Capecitabine—esophageal cancer	0.00305	0.0227	CcSEcCtD
Lithium—Peripheral coldness—Capecitabine—esophageal cancer	0.00301	0.0224	CcSEcCtD
Lithium—Hypothyroidism—Capecitabine—esophageal cancer	0.00223	0.0166	CcSEcCtD
Lithium—Hypercalcaemia—Capecitabine—esophageal cancer	0.00206	0.0153	CcSEcCtD
Lithium—Dysarthria—Cisplatin—esophageal cancer	0.00205	0.0153	CcSEcCtD
Lithium—Body temperature increased—Carboplatin—esophageal cancer	0.00187	0.0139	CcSEcCtD
Lithium—Skin ulcer—Capecitabine—esophageal cancer	0.00184	0.0137	CcSEcCtD
Lithium—Memory impairment—Capecitabine—esophageal cancer	0.00182	0.0136	CcSEcCtD
Lithium—Folliculitis—Methotrexate—esophageal cancer	0.0017	0.0126	CcSEcCtD
Lithium—Psoriasis—Methotrexate—esophageal cancer	0.0017	0.0126	CcSEcCtD
Lithium—Chest discomfort—Capecitabine—esophageal cancer	0.00162	0.012	CcSEcCtD
Lithium—Polyuria—Cisplatin—esophageal cancer	0.00161	0.0119	CcSEcCtD
Lithium—Dysarthria—Capecitabine—esophageal cancer	0.00151	0.0113	CcSEcCtD
Lithium—Coordination abnormal—Capecitabine—esophageal cancer	0.00146	0.0108	CcSEcCtD
Lithium—Stupor—Methotrexate—esophageal cancer	0.00143	0.0106	CcSEcCtD
Lithium—Urinary incontinence—Capecitabine—esophageal cancer	0.00138	0.0103	CcSEcCtD
Lithium—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00138	0.0103	CcSEcCtD
Lithium—Skin ulcer—Methotrexate—esophageal cancer	0.00137	0.0102	CcSEcCtD
Lithium—Dehydration—Cisplatin—esophageal cancer	0.00131	0.00975	CcSEcCtD
Lithium—Urine output increased—Capecitabine—esophageal cancer	0.00129	0.00962	CcSEcCtD
Lithium—Polyuria—Capecitabine—esophageal cancer	0.00118	0.0088	CcSEcCtD
Lithium—Swelling—Capecitabine—esophageal cancer	0.00118	0.00876	CcSEcCtD
Lithium—Oliguria—Methotrexate—esophageal cancer	0.00116	0.0086	CcSEcCtD
Lithium—Dysarthria—Methotrexate—esophageal cancer	0.00113	0.00838	CcSEcCtD
Lithium—Thirst—Capecitabine—esophageal cancer	0.00109	0.00812	CcSEcCtD
Lithium—Lethargy—Capecitabine—esophageal cancer	0.00106	0.00789	CcSEcCtD
Lithium—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00103	0.00765	CcSEcCtD
Lithium—Bradycardia—Cisplatin—esophageal cancer	0.000993	0.00738	CcSEcCtD
Lithium—Ataxia—Capecitabine—esophageal cancer	0.000977	0.00727	CcSEcCtD
Lithium—Coma—Methotrexate—esophageal cancer	0.000974	0.00724	CcSEcCtD
Lithium—Dehydration—Capecitabine—esophageal cancer	0.000967	0.00719	CcSEcCtD
Lithium—Urine output increased—Methotrexate—esophageal cancer	0.000964	0.00716	CcSEcCtD
Lithium—Dry skin—Capecitabine—esophageal cancer	0.000953	0.00708	CcSEcCtD
Lithium—Gastritis—Capecitabine—esophageal cancer	0.00092	0.00684	CcSEcCtD
Lithium—Muscular weakness—Capecitabine—esophageal cancer	0.000917	0.00681	CcSEcCtD
Lithium—Tinnitus—Cisplatin—esophageal cancer	0.000909	0.00676	CcSEcCtD
Lithium—Polyuria—Methotrexate—esophageal cancer	0.000881	0.00655	CcSEcCtD
Lithium—Arrhythmia—Cisplatin—esophageal cancer	0.000871	0.00648	CcSEcCtD
Lithium—Alopecia—Cisplatin—esophageal cancer	0.000862	0.00641	CcSEcCtD
Lithium—Flatulence—Cisplatin—esophageal cancer	0.000837	0.00622	CcSEcCtD
Lithium—Weight increased—Capecitabine—esophageal cancer	0.000818	0.00608	CcSEcCtD
Lithium—Weight decreased—Capecitabine—esophageal cancer	0.000813	0.00604	CcSEcCtD
Lithium—Hyperglycaemia—Capecitabine—esophageal cancer	0.00081	0.00602	CcSEcCtD
Lithium—Vision blurred—Cisplatin—esophageal cancer	0.0008	0.00595	CcSEcCtD
Lithium—Tremor—Cisplatin—esophageal cancer	0.000796	0.00591	CcSEcCtD
Lithium—Lethargy—Methotrexate—esophageal cancer	0.00079	0.00587	CcSEcCtD
Lithium—Convulsion—Cisplatin—esophageal cancer	0.000736	0.00547	CcSEcCtD
Lithium—Bradycardia—Capecitabine—esophageal cancer	0.000732	0.00544	CcSEcCtD
Lithium—Ataxia—Methotrexate—esophageal cancer	0.000728	0.00541	CcSEcCtD
Lithium—Discomfort—Cisplatin—esophageal cancer	0.000714	0.00531	CcSEcCtD
Lithium—Oedema—Cisplatin—esophageal cancer	0.000693	0.00515	CcSEcCtD
Lithium—Tinnitus—Capecitabine—esophageal cancer	0.00067	0.00498	CcSEcCtD
Lithium—Anorexia—Cisplatin—esophageal cancer	0.000661	0.00491	CcSEcCtD
Lithium—Hypotension—Cisplatin—esophageal cancer	0.000648	0.00481	CcSEcCtD
Lithium—Arrhythmia—Capecitabine—esophageal cancer	0.000642	0.00478	CcSEcCtD
Lithium—Alopecia—Capecitabine—esophageal cancer	0.000635	0.00472	CcSEcCtD
Lithium—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000631	0.00469	CcSEcCtD
Lithium—Flatulence—Capecitabine—esophageal cancer	0.000617	0.00459	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—esophageal cancer	0.000616	0.00458	CcSEcCtD
Lithium—Dysgeusia—Capecitabine—esophageal cancer	0.000613	0.00456	CcSEcCtD
Lithium—Decreased appetite—Cisplatin—esophageal cancer	0.000602	0.00448	CcSEcCtD
Lithium—Drowsiness—Methotrexate—esophageal cancer	0.000596	0.00443	CcSEcCtD
Lithium—Vision blurred—Capecitabine—esophageal cancer	0.00059	0.00439	CcSEcCtD
Lithium—Tremor—Capecitabine—esophageal cancer	0.000586	0.00436	CcSEcCtD
Lithium—Feeling abnormal—Cisplatin—esophageal cancer	0.000571	0.00425	CcSEcCtD
Lithium—Vertigo—Capecitabine—esophageal cancer	0.000562	0.00418	CcSEcCtD
Lithium—Syncope—Capecitabine—esophageal cancer	0.000561	0.00417	CcSEcCtD
Lithium—Loss of consciousness—Capecitabine—esophageal cancer	0.00055	0.00409	CcSEcCtD
Lithium—Body temperature increased—Cisplatin—esophageal cancer	0.000548	0.00407	CcSEcCtD
Lithium—Arthralgia—Capecitabine—esophageal cancer	0.000533	0.00396	CcSEcCtD
Lithium—Discomfort—Capecitabine—esophageal cancer	0.000527	0.00391	CcSEcCtD
Lithium—Dry mouth—Capecitabine—esophageal cancer	0.000521	0.00387	CcSEcCtD
Lithium—Confusional state—Capecitabine—esophageal cancer	0.000515	0.00383	CcSEcCtD
Lithium—Oedema—Capecitabine—esophageal cancer	0.000511	0.0038	CcSEcCtD
Lithium—Shock—Capecitabine—esophageal cancer	0.000503	0.00374	CcSEcCtD
Lithium—Tinnitus—Methotrexate—esophageal cancer	0.000499	0.00371	CcSEcCtD
Lithium—Asthenia—Cisplatin—esophageal cancer	0.000497	0.0037	CcSEcCtD
Lithium—Anorexia—Capecitabine—esophageal cancer	0.000487	0.00362	CcSEcCtD
Lithium—Hypotension—Capecitabine—esophageal cancer	0.000477	0.00355	CcSEcCtD
Lithium—Diarrhoea—Cisplatin—esophageal cancer	0.000474	0.00353	CcSEcCtD
Lithium—Alopecia—Methotrexate—esophageal cancer	0.000473	0.00352	CcSEcCtD
Lithium—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000465	0.00346	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—esophageal cancer	0.000456	0.00339	CcSEcCtD
Lithium—Dyspepsia—Capecitabine—esophageal cancer	0.00045	0.00334	CcSEcCtD
Lithium—Decreased appetite—Capecitabine—esophageal cancer	0.000444	0.0033	CcSEcCtD
Lithium—Vomiting—Cisplatin—esophageal cancer	0.000441	0.00328	CcSEcCtD
Lithium—Fatigue—Capecitabine—esophageal cancer	0.00044	0.00327	CcSEcCtD
Lithium—Vision blurred—Methotrexate—esophageal cancer	0.000439	0.00326	CcSEcCtD
Lithium—Rash—Cisplatin—esophageal cancer	0.000437	0.00325	CcSEcCtD
Lithium—Dermatitis—Cisplatin—esophageal cancer	0.000437	0.00325	CcSEcCtD
Lithium—Feeling abnormal—Capecitabine—esophageal cancer	0.000421	0.00313	CcSEcCtD
Lithium—Vertigo—Methotrexate—esophageal cancer	0.000419	0.00311	CcSEcCtD
Lithium—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000418	0.00311	CcSEcCtD
Lithium—Nausea—Cisplatin—esophageal cancer	0.000412	0.00306	CcSEcCtD
Lithium—Abdominal pain—Capecitabine—esophageal cancer	0.000404	0.003	CcSEcCtD
Lithium—Body temperature increased—Capecitabine—esophageal cancer	0.000404	0.003	CcSEcCtD
Lithium—Convulsion—Methotrexate—esophageal cancer	0.000404	0.003	CcSEcCtD
Lithium—Arthralgia—Methotrexate—esophageal cancer	0.000397	0.00295	CcSEcCtD
Lithium—Discomfort—Methotrexate—esophageal cancer	0.000392	0.00291	CcSEcCtD
Lithium—Confusional state—Methotrexate—esophageal cancer	0.000383	0.00285	CcSEcCtD
Lithium—Asthenia—Capecitabine—esophageal cancer	0.000367	0.00272	CcSEcCtD
Lithium—Anorexia—Methotrexate—esophageal cancer	0.000362	0.00269	CcSEcCtD
Lithium—Hypotension—Methotrexate—esophageal cancer	0.000355	0.00264	CcSEcCtD
Lithium—Diarrhoea—Capecitabine—esophageal cancer	0.00035	0.0026	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000346	0.00258	CcSEcCtD
Lithium—Somnolence—Methotrexate—esophageal cancer	0.000338	0.00251	CcSEcCtD
Lithium—Dizziness—Capecitabine—esophageal cancer	0.000338	0.00251	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—esophageal cancer	0.000335	0.00249	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—esophageal cancer	0.000331	0.00246	CcSEcCtD
Lithium—Fatigue—Methotrexate—esophageal cancer	0.000328	0.00244	CcSEcCtD
Lithium—Vomiting—Capecitabine—esophageal cancer	0.000325	0.00241	CcSEcCtD
Lithium—Rash—Capecitabine—esophageal cancer	0.000322	0.00239	CcSEcCtD
Lithium—Dermatitis—Capecitabine—esophageal cancer	0.000322	0.00239	CcSEcCtD
Lithium—Headache—Capecitabine—esophageal cancer	0.00032	0.00238	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—esophageal cancer	0.000313	0.00233	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000311	0.00231	CcSEcCtD
Lithium—Nausea—Capecitabine—esophageal cancer	0.000303	0.00226	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—esophageal cancer	0.000301	0.00223	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—esophageal cancer	0.000301	0.00223	CcSEcCtD
Lithium—Asthenia—Methotrexate—esophageal cancer	0.000273	0.00203	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—esophageal cancer	0.00026	0.00193	CcSEcCtD
Lithium—Dizziness—Methotrexate—esophageal cancer	0.000251	0.00187	CcSEcCtD
Lithium—Vomiting—Methotrexate—esophageal cancer	0.000242	0.0018	CcSEcCtD
Lithium—Rash—Methotrexate—esophageal cancer	0.00024	0.00178	CcSEcCtD
Lithium—Dermatitis—Methotrexate—esophageal cancer	0.00024	0.00178	CcSEcCtD
Lithium—Headache—Methotrexate—esophageal cancer	0.000238	0.00177	CcSEcCtD
Lithium—Nausea—Methotrexate—esophageal cancer	0.000226	0.00168	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—esophageal cancer	0.000211	0.000321	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—CDKN1A—esophageal cancer	0.00021	0.00032	CbGpPWpGaD
Lithium—IMPA2—Metabolism—NOS3—esophageal cancer	0.000209	0.000319	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—PIK3CA—esophageal cancer	0.000209	0.000318	CbGpPWpGaD
Lithium—GSK3A—Disease—B2M—esophageal cancer	0.000209	0.000318	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CREBBP—esophageal cancer	0.000208	0.000317	CbGpPWpGaD
Lithium—GSK3B—Disease—ELMO1—esophageal cancer	0.000208	0.000317	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CREBBP—esophageal cancer	0.000208	0.000316	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—esophageal cancer	0.000208	0.000316	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—esophageal cancer	0.000207	0.000314	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000206	0.000313	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—esophageal cancer	0.000206	0.000313	CbGpPWpGaD
Lithium—GSK3A—Immune System—CALR—esophageal cancer	0.000205	0.000312	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—esophageal cancer	0.000204	0.000311	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TLR4—esophageal cancer	0.000204	0.00031	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—EP300—esophageal cancer	0.000204	0.00031	CbGpPWpGaD
Lithium—GSK3B—Disease—TPI1—esophageal cancer	0.000204	0.00031	CbGpPWpGaD
Lithium—GSK3B—Disease—GSTO1—esophageal cancer	0.000204	0.00031	CbGpPWpGaD
Lithium—GSK3B—Immune System—CFL1—esophageal cancer	0.000204	0.00031	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—WWOX—esophageal cancer	0.000202	0.000308	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—esophageal cancer	0.000202	0.000307	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—PIK3CA—esophageal cancer	0.0002	0.000305	CbGpPWpGaD
Lithium—GSK3A—Disease—ENO1—esophageal cancer	0.0002	0.000305	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	0.0002	0.000305	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ABL1—esophageal cancer	0.000199	0.000303	CbGpPWpGaD
Lithium—GSK3A—Immune System—FBXW7—esophageal cancer	0.000198	0.000302	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ELMO1—esophageal cancer	0.000197	0.0003	CbGpPWpGaD
Lithium—GSK3A—Disease—PSME2—esophageal cancer	0.000197	0.0003	CbGpPWpGaD
Lithium—GSK3A—Disease—PSME1—esophageal cancer	0.000197	0.0003	CbGpPWpGaD
Lithium—GSK3B—Disease—ALDOB—esophageal cancer	0.000195	0.000297	CbGpPWpGaD
Lithium—GSK3B—Immune System—LGALS3—esophageal cancer	0.000195	0.000297	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKAP13—esophageal cancer	0.000193	0.000294	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FKBP1A—esophageal cancer	0.000193	0.000293	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—esophageal cancer	0.000192	0.000293	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—esophageal cancer	0.000192	0.000293	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—esophageal cancer	0.000192	0.000293	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—PIK3CA—esophageal cancer	0.000192	0.000292	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—esophageal cancer	0.000192	0.000291	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—EP300—esophageal cancer	0.000191	0.000291	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—esophageal cancer	0.000191	0.00029	CbGpPWpGaD
Lithium—GSK3A—Immune System—HMGB1—esophageal cancer	0.00019	0.000288	CbGpPWpGaD
Lithium—GSK3A—Disease—CALR—esophageal cancer	0.000189	0.000288	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB2—esophageal cancer	0.000189	0.000288	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—esophageal cancer	0.000189	0.000288	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—PIK3CA—esophageal cancer	0.000189	0.000287	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—WIF1—esophageal cancer	0.000188	0.000286	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—esophageal cancer	0.000188	0.000286	CbGpPWpGaD
Lithium—GSK3B—Disease—HIST1H2BM—esophageal cancer	0.000188	0.000286	CbGpPWpGaD
Lithium—GSK3B—Disease—GAPDH—esophageal cancer	0.000188	0.000286	CbGpPWpGaD
Lithium—IMPA1—Metabolism—NOS3—esophageal cancer	0.000187	0.000284	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—EP300—esophageal cancer	0.000185	0.000281	CbGpPWpGaD
Lithium—GSK3A—Disease—FBXW7—esophageal cancer	0.000183	0.000279	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—esophageal cancer	0.000182	0.000277	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—PIK3CA—esophageal cancer	0.000181	0.000275	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—PIK3CA—esophageal cancer	0.00018	0.000274	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—PIK3CA—esophageal cancer	0.000179	0.000273	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—PIK3CA—esophageal cancer	0.000178	0.000271	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000178	0.000271	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—esophageal cancer	0.000178	0.000271	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—PIK3CA—esophageal cancer	0.000177	0.00027	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—esophageal cancer	0.000177	0.00027	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDE4D—esophageal cancer	0.000177	0.000269	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CASP8—esophageal cancer	0.000175	0.000266	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—esophageal cancer	0.000175	0.000266	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CREBBP—esophageal cancer	0.000174	0.000265	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000174	0.000264	CbGpPWpGaD
Lithium—GSK3B—Immune System—ACTB—esophageal cancer	0.000173	0.000263	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN1A—esophageal cancer	0.000172	0.000262	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—EP300—esophageal cancer	0.000172	0.000261	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ERBB2—esophageal cancer	0.000171	0.00026	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KDR—esophageal cancer	0.000171	0.00026	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—esophageal cancer	0.000171	0.00026	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—esophageal cancer	0.00017	0.000259	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTPN2—esophageal cancer	0.000169	0.000257	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GNG7—esophageal cancer	0.000168	0.000255	CbGpPWpGaD
Lithium—GSK3B—Immune System—B2M—esophageal cancer	0.000167	0.000254	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MET—esophageal cancer	0.000167	0.000254	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—PIK3CA—esophageal cancer	0.000167	0.000254	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—PIK3CA—esophageal cancer	0.000167	0.000254	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—PIK3CA—esophageal cancer	0.000167	0.000254	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—MYC—esophageal cancer	0.000167	0.000253	CbGpPWpGaD
Lithium—GSK3B—Disease—XIAP—esophageal cancer	0.000166	0.000253	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—PIK3CA—esophageal cancer	0.000165	0.000252	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—PIK3CA—esophageal cancer	0.000164	0.00025	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—EP300—esophageal cancer	0.000164	0.000249	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—PIK3CA—esophageal cancer	0.000163	0.000248	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PFN1—esophageal cancer	0.000162	0.000247	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—CDKN1A—esophageal cancer	0.000162	0.000246	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—esophageal cancer	0.000161	0.000245	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NOTCH1—esophageal cancer	0.000161	0.000245	CbGpPWpGaD
Lithium—IMPA2—Metabolism—EP300—esophageal cancer	0.000159	0.000242	CbGpPWpGaD
Lithium—GSK3B—Immune System—PSME2—esophageal cancer	0.000158	0.00024	CbGpPWpGaD
Lithium—GSK3B—Immune System—PSME1—esophageal cancer	0.000158	0.00024	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—PIK3CA—esophageal cancer	0.000158	0.00024	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—XIAP—esophageal cancer	0.000157	0.000239	CbGpPWpGaD
Lithium—GSK3A—Immune System—ABL1—esophageal cancer	0.000157	0.000239	CbGpPWpGaD
Lithium—GSK3B—Immune System—HSPA5—esophageal cancer	0.000156	0.000238	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PIK3CA—esophageal cancer	0.000155	0.000235	CbGpPWpGaD
Lithium—GSK3B—Disease—B2M—esophageal cancer	0.000154	0.000235	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PIK3CA—esophageal cancer	0.000154	0.000234	CbGpPWpGaD
Lithium—GSK3B—Immune System—CALR—esophageal cancer	0.000152	0.000231	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR4—esophageal cancer	0.000151	0.000229	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—BCL2—esophageal cancer	0.00015	0.000229	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—esophageal cancer	0.00015	0.000228	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNA1—esophageal cancer	0.000149	0.000226	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFBR2—esophageal cancer	0.000148	0.000225	CbGpPWpGaD
Lithium—GSK3B—Disease—ENO1—esophageal cancer	0.000148	0.000225	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL2—esophageal cancer	0.000148	0.000225	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	0.000148	0.000225	CbGpPWpGaD
Lithium—GSK3B—Immune System—FBXW7—esophageal cancer	0.000147	0.000223	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—esophageal cancer	0.000146	0.000222	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ELMO1—esophageal cancer	0.000146	0.000222	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—esophageal cancer	0.000146	0.000222	CbGpPWpGaD
Lithium—GSK3B—Disease—PSME2—esophageal cancer	0.000146	0.000222	CbGpPWpGaD
Lithium—GSK3B—Disease—PSME1—esophageal cancer	0.000146	0.000222	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CREBBP—esophageal cancer	0.000146	0.000222	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKAP13—esophageal cancer	0.000143	0.000217	CbGpPWpGaD
Lithium—IMPA1—Metabolism—EP300—esophageal cancer	0.000142	0.000216	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—EP300—esophageal cancer	0.000142	0.000215	CbGpPWpGaD
Lithium—GSK3A—Disease—SMAD4—esophageal cancer	0.00014	0.000213	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—esophageal cancer	0.00014	0.000213	CbGpPWpGaD
Lithium—GSK3B—Immune System—HMGB1—esophageal cancer	0.00014	0.000213	CbGpPWpGaD
Lithium—GSK3B—Disease—CALR—esophageal cancer	0.00014	0.000213	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PSME1—esophageal cancer	0.000138	0.00021	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PSME2—esophageal cancer	0.000138	0.00021	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ANXA1—esophageal cancer	0.000138	0.000209	CbGpPWpGaD
Lithium—GSK3B—Disease—FBXW7—esophageal cancer	0.000135	0.000206	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SST—esophageal cancer	0.000134	0.000204	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000132	0.0002	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—esophageal cancer	0.000131	0.000199	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDE4D—esophageal cancer	0.00013	0.000198	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GHRL—esophageal cancer	0.00013	0.000198	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH3—esophageal cancer	0.00013	0.000198	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CASP8—esophageal cancer	0.000129	0.000197	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CREBBP—esophageal cancer	0.000129	0.000196	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FBXW7—esophageal cancer	0.000128	0.000195	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1A—esophageal cancer	0.000125	0.00019	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNG7—esophageal cancer	0.000124	0.000189	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—esophageal cancer	0.000123	0.000188	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—esophageal cancer	0.000122	0.000186	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1A—esophageal cancer	0.00012	0.000182	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR4—esophageal cancer	0.000119	0.000181	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EP300—esophageal cancer	0.000119	0.000181	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—esophageal cancer	0.000119	0.00018	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—esophageal cancer	0.000118	0.000179	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—esophageal cancer	0.000117	0.000179	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH2—esophageal cancer	0.000117	0.000178	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—XIAP—esophageal cancer	0.000116	0.000177	CbGpPWpGaD
Lithium—GSK3B—Immune System—ABL1—esophageal cancer	0.000116	0.000176	CbGpPWpGaD
Lithium—GSK3A—Disease—HIF1A—esophageal cancer	0.000115	0.000175	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—esophageal cancer	0.000114	0.000173	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BCL2—esophageal cancer	0.000111	0.000169	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNA1—esophageal cancer	0.00011	0.000167	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFBR2—esophageal cancer	0.000109	0.000167	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL2—esophageal cancer	0.000109	0.000166	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—esophageal cancer	0.000108	0.000164	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—esophageal cancer	0.000105	0.00016	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—esophageal cancer	0.000104	0.000159	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFBR2—esophageal cancer	0.000104	0.000158	CbGpPWpGaD
Lithium—GSK3B—Disease—SMAD4—esophageal cancer	0.000104	0.000158	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—esophageal cancer	0.000104	0.000158	CbGpPWpGaD
Lithium—GSK3A—Disease—NOTCH1—esophageal cancer	0.000103	0.000157	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSME1—esophageal cancer	0.000102	0.000155	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSME2—esophageal cancer	0.000102	0.000155	CbGpPWpGaD
Lithium—GSK3A—Immune System—CASP8—esophageal cancer	0.000102	0.000155	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ANXA1—esophageal cancer	0.000102	0.000155	CbGpPWpGaD
Lithium—GSK3A—Immune System—CREBBP—esophageal cancer	0.000102	0.000154	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—esophageal cancer	0.000101	0.000154	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EP300—esophageal cancer	9.93e-05	0.000151	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SST—esophageal cancer	9.89e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMAD4—esophageal cancer	9.82e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—esophageal cancer	9.71e-05	0.000148	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH3—esophageal cancer	9.63e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GHRL—esophageal cancer	9.63e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FBXW7—esophageal cancer	9.48e-05	0.000144	CbGpPWpGaD
Lithium—GSK3A—Disease—CREBBP—esophageal cancer	9.37e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1A—esophageal cancer	9.22e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1A—esophageal cancer	8.85e-05	0.000135	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—esophageal cancer	8.78e-05	0.000134	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—esophageal cancer	8.78e-05	0.000134	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—esophageal cancer	8.77e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2—esophageal cancer	8.75e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH2—esophageal cancer	8.64e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—esophageal cancer	8.5e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—esophageal cancer	8.48e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—esophageal cancer	8.46e-05	0.000129	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—esophageal cancer	8.43e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS3—esophageal cancer	8.39e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—esophageal cancer	8.03e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—esophageal cancer	7.85e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—esophageal cancer	7.71e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—esophageal cancer	7.68e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—esophageal cancer	7.67e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFBR2—esophageal cancer	7.67e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Disease—NOTCH1—esophageal cancer	7.64e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP8—esophageal cancer	7.53e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREBBP—esophageal cancer	7.5e-05	0.000114	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—esophageal cancer	7.48e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—esophageal cancer	7.27e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMAD4—esophageal cancer	7.26e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH1—esophageal cancer	7.24e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—esophageal cancer	7.18e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Disease—CREBBP—esophageal cancer	6.92e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—esophageal cancer	6.91e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—esophageal cancer	6.71e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREBBP—esophageal cancer	6.56e-05	9.99e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—esophageal cancer	6.49e-05	9.87e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2—esophageal cancer	6.47e-05	9.84e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—esophageal cancer	6.38e-05	9.71e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—esophageal cancer	6.28e-05	9.56e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—esophageal cancer	6.23e-05	9.48e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—esophageal cancer	6.2e-05	9.43e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—esophageal cancer	5.94e-05	9.03e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—esophageal cancer	5.89e-05	8.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—esophageal cancer	5.88e-05	8.94e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—esophageal cancer	5.8e-05	8.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—esophageal cancer	5.68e-05	8.64e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—esophageal cancer	5.67e-05	8.63e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—esophageal cancer	5.56e-05	8.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—esophageal cancer	5.5e-05	8.36e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—esophageal cancer	5.44e-05	8.28e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—esophageal cancer	5.37e-05	8.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH1—esophageal cancer	5.35e-05	8.14e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—esophageal cancer	5.11e-05	7.78e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—esophageal cancer	5.11e-05	7.77e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—esophageal cancer	4.96e-05	7.54e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—esophageal cancer	4.86e-05	7.39e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREBBP—esophageal cancer	4.85e-05	7.38e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—esophageal cancer	4.72e-05	7.18e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—esophageal cancer	4.72e-05	7.18e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—esophageal cancer	4.7e-05	7.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—esophageal cancer	4.47e-05	6.8e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—esophageal cancer	4.35e-05	6.63e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—esophageal cancer	4.34e-05	6.61e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—esophageal cancer	4.11e-05	6.25e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—esophageal cancer	4.06e-05	6.18e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—esophageal cancer	4.02e-05	6.12e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—esophageal cancer	3.89e-05	5.93e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—esophageal cancer	3.81e-05	5.8e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—esophageal cancer	3.78e-05	5.75e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—esophageal cancer	3.59e-05	5.46e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—esophageal cancer	3.49e-05	5.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—esophageal cancer	3.47e-05	5.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—esophageal cancer	3.31e-05	5.03e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—esophageal cancer	3.3e-05	5.03e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—esophageal cancer	3.2e-05	4.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—esophageal cancer	2.88e-05	4.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—esophageal cancer	2.81e-05	4.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—esophageal cancer	2.44e-05	3.72e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—esophageal cancer	2.36e-05	3.6e-05	CbGpPWpGaD
